QLHCQuality of Life Health Corporation, Inc. (Los Angeles, CA)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
The I-SPY 2 Trial, sponsored by QLHC, is a standing phase 2 randomized, controlled, multicenter study aimed to rapidly screen and identify promising new treatments in specific subgroups of women with newly-diagnosed, high-risk, locally-advanced breast cancer.
Healthcare company Quantum Leap Healthcare Collaborative (QLHC) reported on Thursday the launch of a new randomised, investigational treatment arm under the I-SPY 2 TRIAL of olaparib and durvalumab for the treatment of early stage breast cancers with a high risk of recurrence.